Sign In
Buy SGMO
$0.216
+0.0022 (+1.03%)
At Close: Jun 03, 2026
Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call Transcript
11:56pm, Thursday, 06'th Nov 2025
Sangamo Therapeutics, Inc. ( SGMO ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Louise Wilkie - Head of Global Corporate Communications & Investor Relations Alexander Macra
Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates
10:16am, Thursday, 06'th Nov 2025
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.04 per share a year ago.
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results
08:01am, Thursday, 06'th Nov 2025
Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated glomerular filtration rate (eGFR) slope as an endpoint to s
Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call
04:01pm, Thursday, 30'th Oct 2025
RICHMOND, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the company has scheduled the release of its third quart
Totality of data supports potential for isaralgagene civaparvovec as a one-time, durable treatment of the underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits ab
What Makes Sangamo (SGMO) a New Buy Stock
01:01pm, Thursday, 14'th Aug 2025
Sangamo (SGMO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript
02:53pm, Friday, 08'th Aug 2025
Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Alexander D. Macrae - CEO, President & Director Gregory Davis - Head of Resear
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates
06:40pm, Thursday, 07'th Aug 2025
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.17 per share a year ago.
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results
04:01pm, Thursday, 07'th Aug 2025
Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed p
Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call
04:05pm, Thursday, 31'st Jul 2025
RICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its second quart
Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease
08:05am, Tuesday, 24'th Jun 2025
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease.
Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript
09:06pm, Monday, 12'th May 2025
Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q1 2025 Earnings Conference Call May 12, 2025 6:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
06:55pm, Monday, 12'th May 2025
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.27 per share a year ago.
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
06:26pm, Monday, 12'th May 2025
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results.
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering
06:23pm, Monday, 12'th May 2025
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering.
